Why the MedAdvisor (ASX:MDR) share price jumped 12% today

The medication management platform sees strong growth in the US after its "transformational" acquisition 6 months ago.

The MedAdvisor Ltd (ASX: MDR) share price is on the rise today after the company announced a US business update.

The medication management platform provider's shares are currently up 12% to 32.5 cents.

Digitised heart rate and share price chart with man on ipad in background signifying share price

Image source: Getty Images

Why did the MedAdvisor share price push higher?

MedAdvisor has provided a business update 6 months after its acquisition of US-based patient management solutions platform, Adheris.

In today's statement, MedAdvisor advised that its revenue had growth 40% on a like-for-like basis for the 9 months year-to-date for FY21.

MedAdvisor is leveraging Adheris' extensive network of approximately 25,000 pharmacies and 2.2 billion scripts annual to bring additional scale to its digital capabilities.

The rollout of MedAdvisor's digital solutions through the Adheris network is well underway. In June, 17% of the Adheris pharmacy network was scheduled to be digital, and a further 13% is expected in the September quarter.

Pleasingly, this will bring the company's profile of digitally contactable patients in the US to approximately 42 million, or 20 times its present digital reach in Australia.

Additionally, MedAdvisor has rolled out 7 digital programs for pharmaceutical companies in the US. The company says that on average, patients who join the digital program demonstrate an improved adherence of up to 30%, leading to 1–2 extra script fills per year. The company says this results in improved health outcomes for the patients and more consistent revenue for the pharmacy.

Management commentary

MedAdvisor US President, John Ciccio comments on the company's achievements in the US:

We've invested in providing the sales and marketing team with the resources required to go deeper with existing clients and expand our customer base. We've added new customers and brands to our network in the past 6 months and we're selling more multi-tactic programs that include digital.

By expanding its digital offering, MedAdvisor is able to significantly boost the attractiveness of its product suite to its client base. As an example, one top ten pharmaceutical client who has averaged USD$125k p.a. with Adheris over the last 2 years has now signed a multi-channel deal for USD$1 million for CY21.

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended MedAdvisor. The Motley Fool Australia has recommended MedAdvisor. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Technology Shares

A man sitting at his desktop computer leans forward onto his elbows and yawns while he rubs his eyes as though he is very tired.
Technology Shares

3 ASX shares I'd buy if the technology sell-off gets worse

I'm watching these three shares closely, and I'd be happy to buy if their valuations become even more attractive.

Read more »

A silhouette of a soldier flying a drone at sunset.
Technology Shares

If I had $10,000 I had to lock up in one share for a decade, this would be it

This technology manufacturer ticks all the boxes for me.

Read more »

Colourful explosion symbolising ASX share price growth.
Technology Shares

This ASX tech share is surging 47% higher today. Analysts see more upside ahead

The ASX shares have now recouped losses shed earlier this year.

Read more »

A man and woman high five each while sitting down after working out at the gym.
Technology Shares

3 reasons to buy Catapult Sports shares after crashing 17% on results day

The market didn't like the latest results, but I think there's more to the story than the widening loss.

Read more »

Rocket going up above mountains, symbolising a record high.
Technology Shares

This company has almost no revenue. So why are its shares up nearly 10 times?

A collaboration with Amazon has investors interested.

Read more »

Work colleagues discussing finance charts and graphs on a laptop computer and tablet in their office.
Technology Shares

3 reasons I'd buy TechnologyOne shares after today's strong FY26 results

I've been looking through today's figures, and three things have given me more confidence in the company's growth prospects.

Read more »

Magnifying glass in front of an open newspaper with paper houses.
Technology Shares

Is this tiny ASX tech company in the sights of a takeover suitor?

A sudden share price surge could suggest something is in the wings.

Read more »

AI written in blue on a digital chip.
Technology Shares

Australians can now apply for Anthropic shares. What are the pros and cons?

This company's growth rates are staggering.

Read more »